ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

Core Insights - ARS Pharmaceuticals, Inc. is focused on empowering at-risk patients and caregivers to manage allergic reactions that may lead to anaphylaxis [1][6] - The company will have key presentations at the William Blair 45 Annual Growth Stock Conference and the 2025 Jefferies Global Healthcare Conference in June [1][4] Event Details - William Blair 45 Annual Growth Stock Conference - Presentation Date: June 3, 2025 - Time: 11:20 a.m. CT - Location: Chicago [3] - 2025 Jefferies Global Healthcare Conference - Presentation Date: June 4, 2025 - Time: 5:30 p.m. ET - Location: New York City [4] - The company will also engage in one-on-one meetings with investors at the Scotiabank Third Annual Healthcare Canadian Investor Day on June 17, 2025, in Toronto [4] Product Information - ARS Pharmaceuticals is commercializing neffy (trade name EURneffy in the EU), an epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis [6] - In the U.S., neffy is indicated for adult and pediatric patients aged 4 years and older who weigh 15 kg or more [6] - In the EU, it is indicated for emergency treatment of allergic reactions due to various allergens in adults and children who weigh 30 kg or more [6]